Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Galapagos NV    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Amsterdam
04/06/2021 04/07/2021 04/08/2021 04/09/2021 04/12/2021 Date
67(c) 65.1(c) 65.56(c) 65.55(c) 64.71(c) Last
476 379 394 236 295 142 451 175 445 877 Volume
-0.56% -2.84% +0.71% -0.02% -1.28% Change
More quotes
Financials
Sales 2021 455 M 542 M 542 M
Net income 2021 -299 M -356 M -356 M
Net cash position 2021 3 566 M 4 246 M 4 246 M
P/E ratio 2021 -15,3x
Yield 2021 -
Sales 2022 515 M 613 M 613 M
Net income 2022 -276 M -329 M -329 M
Net cash position 2022 3 264 M 3 886 M 3 886 M
P/E ratio 2022 -15,0x
Yield 2022 -
Capitalization 4 239 M 5 050 M 5 047 M
EV / Sales 2021 1,48x
EV / Sales 2022 1,89x
Nbr of Employees 1 489
Free-Float 73,7%
More Financials
Company
Galapagos NV specializes in the research and development of drugs based on novel targets discovered and validated in human primary cells. Net sales break down by activity as follows: - discovery and development of drugs (98.8%); - other (1.2%). Net sales are distributed geographically as follows: Europe (5.8%) and North America (94.2%). 
Sector
Biotechnology & Medical Research
Calendar
04/28 | 08:00amShareholder meeting
More about the company
Notations Surperformance© of Galapagos NV
Trading Rating : Investor Rating :
More Ratings
All news about GALAPAGOS NV
04/09GALAPAGOS  : Gilead Extends Lock-Up Period for Galapagos Shareholding
MT
04/08GALAPAGOS  : Extension of lock-up period in Gilead-Galapagos collaboration agree..
AQ
03/26GALAPAGOS NV  : - Publication of the annual report and invitation to the ordinar..
AQ
03/25GALAPAGOS  : Statutory auditor's report on the non-consolidated financial statem..
PU
03/25GALAPAGOS  : Publication of the annual report and invitation to the ordinary sha..
AQ
03/25GALAPAGOS  : COO Takes On President Role
MT
03/24GALAPAGOS  : Names Bart Filius President & COO
MT
03/24Galapagos appoints Bart Filius as President and Chief Operating Officer
GL
03/19GALAPAGOS  : increases share capital through subscription right exercises
AQ
03/19GALAPAGOS NV  : Crossing thresholds
CO
03/18Oxurion NV Business and Financial Update, FY 2020
AQ
03/04GALAPAGOS  : Says Ongoing Anti-inflammatory Drug Trials Meet Primary Endpoint
MT
03/04GALAPAGOS NV  : - Transparency notification received from The Capital Group
AQ
03/04GALAPAGOS  : REPORTS PRIMARY ENDPOINT FOR THE ONGOING FILGOTINIB MANTA AND MANTA..
AQ
03/03Transparency notification received from The Capital Group
GL
More news
News in other languages on GALAPAGOS NV
03/10GALAPAGOS  : vers une sortie de l'AEX
03/10EN DIRECT DES MARCHES  : EDF, Stellantis, Alstom, Rothschild, Voyageurs du Monde..
02/22AVIS D'ANALYSTES DU JOUR  : Kering, Hermès, Logitech, Air France, Varta, GTT, At..
02/11AVIS D'ANALYSTES DU JOUR  : Airbus, Adyen, Eurofins, Galapagos, Orpea, Sartorius..
02/10GALAPAGOS NV  : en échec sur ziritaxestat, plongeon en bourse
More news
Analyst Recommendations on GALAPAGOS NV
More recommendations
Chart GALAPAGOS NV
Duration : Period :
Galapagos NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALAPAGOS NV
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Average target price 71,61 €
Last Close Price 64,71 €
Spread / Highest target 31,4%
Spread / Average Target 10,7%
Spread / Lowest Target -4,19%
EPS Revisions
Managers and Directors
NameTitle
Onno van de Stolpe Chief Executive Officer
Bart Filius President & Chief Operating Officer
Raj B. Parekh Chairman
Piet Wigerinck Chief Scientific Officer
Walid Abi-Saab Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
GALAPAGOS NV-19.59%5 103
MODERNA, INC.34.89%56 442
LONZA GROUP AG-3.59%43 993
IQVIA HOLDINGS INC.15.90%39 822
CELLTRION, INC.-13.51%37 705
SEAGEN INC.-18.44%25 900